The hSNF5 chromatin-remodeling factor is a tumor suppressor that is inactivated in malignant rhabdoid tumors (MRTs). A number of studies have shown that hSNF5 re-expression blocks MRT cell proliferation. However, the pathway through which hSNF5 acts remains unknown. To address this question, we generated MRT-derived cell lines in which restoration of hSNF5 expression leads to an accumulation in G 0 /G 1 , induces cellular senescence and increased apoptosis. Following hSNF5 expression, we observed transcriptional activation of the tumor suppressor p16
The genesis of most human cancers requires disabling of the p53 or retinoblastoma protein (pRb) 1 tumor suppressor pathways, which form the primary cell-autonomous defense against unrestrained proliferation (1) . The activities of these two pathways are modulated by p14 ARF and p16 INK4a , two structurally unrelated proteins encoded by a single locus (2) (3) (4) . These two tumor suppressors act through distinct mechanisms. Whereas p16
INK4a modulates pRb activity, p14 ARF regulates p53 function. pRb is a corepressor that binds several E2F family transcription factors to silence a host of genes required for cell cycle advancement from G 1 to S-phase. In the presence of growthpromoting signals, the cyclin D1-CDK4 complex phosphorylates pRb, causing its dissociation from E2F. This in turn allows activation of E2F responsive genes, driving cell cycle progression into S-phase. p16
INK4a regulates pRb through inhibition of the cyclin D1-CDK4 kinase activity, thus keeping pRb in its active antiproliferative state. The second tumor suppressor encoded by the INK4a/ARF locus, p14
ARF , binds HDM2 to prevent p53 degradation. Stabilization of the p53 transcription factor activates gene expression programs that can lead to cell cycle arrest or apoptosis.
ATP-dependent chromatin-remodeling factors (remodelers) play a crucial role in the regulation of gene expression during cellular differentiation and development (5, 6) . Consequently, aberrant gene control due to mutations in chromatin-regulating enzymes can lead to tumor formation (7) . The multiprotein SWI/SNF complex is the prototypical remodeler, present in all eukaryotes (8 -11) . SWI/SNF utilizes the energy derived from ATP-hydrolysis by its SWI2/SNF2-related ATPase subunit to alter nucleosome structure. Human SWI/SNF complexes (hSWI/SNF or BRM/BRG1-associated factor (BAF) complex) contain either BRM or BRG1, the two SWI2/SNF2p homologues present in human cells.
Several studies have implicated misregulation of SWI/SNF in the development of human cancers (7) . The central BRG1/ BRM ATPases are mutated in multiple human tumor cell lines and their loss correlates with poor prognosis of non-small cell lung cancers (12, 13) . A role for SWI/SNF in tumorgenesis is further supported by its association with proteins with a wellestablished role in human cancers including pRb, BRCA1, MLL, and ␤-catenin (7, 14 -21) . Most compellingly, the human SNF5 gene (hSNF5, a.k.a. Ini1, Baf47, or SmarcB1), encoding a core hSWI/SNF component, was found to be deleted or mutated in virtually all atypical teratoid and malignant rhabdoid tumors (ATRT and MRT) (22, 23) . These rare cancers of early childhood have a grim prognosis and very high lethality. hSNF5 mutations were also found associated with a number of other neoplasms, including chronic myeloid leukemia, choroid plexus carcinoma, medulloblastoma, and central primitive neurectodermal tumors (24, 25) . In addition to somatic mutations, germ-line mutations have been identified. Carriers are predisposed to various cancers, including MRTs and tumors of the central nervous system (23, 26, 27) . In a large proportion of these tumors, the wild-type allele is either lost or deleted, consistent with a classic tumor suppressor phenotype.
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binding regulators (28 -30) , stimulates the in vitro remodeling activity of BRG1 (31) , and is required during postrecruitment remodeling in vivo (32) . Gene inactivation studies in mice revealed that, while homozygous SNF5-null mice die very early during embryogenesis, heterozygous mice survive but are prone to soft tissue tumors (33) (34) (35) . The loss of the remaining SNF5 allele in these tumors strongly suggests that SNF5 functions as a tumor suppressor. Likewise, mice with mono-allelic BRG1 expression are predisposed to tumors, reinforcing the role of SWI/SNF in neoplasia (36) . Utilizing a reversibly inactivating conditional allele, Orkin and co-workers (37) showed that loss of SNF5 function resulted in a highly penetrant and extremely short latency development of cancers, in particular lymphomas or rhabdoid tumors. Their elegant approach, which circumvents the critical requirement for SNF5 during development, highlighted its essential tumor suppression function. This study, however, also uncovered the requirement of SNF5 for survival of most normal, nonmalignant cells. However, when particular additional mutations are present, loss of SNF5 may trigger tumor progression.
The human pediatric cancers and the mouse gene inactivation studies have firmly established SNF5 as a novel tumor suppressor. Moreover, during the course of the present study, a number of reports showed that hSNF5 re-expression blocks MRT cell proliferation (38 -41) . These studies revealed a G 1 cell cycle arrest upon re-expression of hSNF5 in MRT cells. These distinct studies emphasized different targets. Factors reported to be affected by hSNF5 expression include several cyclins, p16
INK4a , and pRb. However, the central question, which of these factors is a critical mediator of hSNF5-induced arrest, remained unsolved.
To address this issue, we have generated MRT-derived cell lines, which inducibly express hSNF5. We found that hSNF5 induction leads to a G 1 cell cycle arrest and cellular senescence. We demonstrate that the transcriptional activation of the tumor suppressor p16
INK4a , but not of p14 ARF , plays a pivotal role in this hSNF5-induced proliferative block. Chromatin immunoprecipitations indicated that the p16
INK4a promoter is an hSNF5-dependent, direct target of the SWI/SNF chromatinremodeling complex. We directly tested the importance of p16
INK4a activity for the hSNF5-induced cell cycle arrest and cellular senescence. Three different approaches, involving p16
INK4a overexpression, the use of a p16 INK4a -insensitive CDK4 and p16
INK4a small interfering RNA duplex (siRNA) knockdown, revealed that p16
INK4a is both necessary and sufficient to mediate hSNF5-dependent cellular senescence. We conclude that in human MRT cells, the p16
INK4a -cyclin D1/ CDK4-pRb pathway, rather than the p14 ARF -HDM2-p53 pathway, is indispensable for hSNF5 tumor suppressor function.
EXPERIMENTAL PROCEDURES
Cell Procedures-Stable cell lines were generated using the LacSwitch TM II system (Stratagene). First pCMVLac1 followed by either pOPRSVI or pOPRSVI-hSNF5-FLAG, generated with a PCR-based strategy, encoding hSNF5 with a C-terminal FLAG epitope, were stably integrated in G401 MRT cells. FuGENE 6 (Roche Applied Science) was used for transfections. The resulting Lac-Empty or Lac-hSNF5 lines were isolated and most experiments were repeated using independent lines. Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM glutamine, 500 g/ml G418, 100 g/ml Hygromycin (Invitrogen), and, when added, 5 mM IPTG. For immunofluorescence, cells were grown on coverslips, fixed with 4% paraformaldehyde, permeabilized in 100% methanol, followed by standard indirect immunofluorescence. Apoptotic cells were identified on the second day following hSNF5 induction by immunofluorescence using rabbit polyclonal 9541 (Cell signaling) antibodies directed against cleaved PARP and mouse monoclonal 6H2.B4 (BD Pharmingen 65971A) antibodies against cytochrome c. Nuclei were visualized by DAPI staining. To determine proliferation curves, 1.5 ϫ 10 5 cells were plated in triplicate into 5 cm dishes. At the indicated time points, cells were harvested and counted. For colony formation, cells were seeded at a density of 3 ϫ 10 3 cells per 9-cm dish. After 7-11 days, cells were fixed with methanol/acetic acid and stained with Giemsa. BrdUrd incorporation was measured according to the manufacturers instructions (BrdUrd labeling and detection kit I, Roche Applied Science). Flow cytometric analyses were typically performed after 3-5 days according to standard procedures (42) . Briefly, cells were washed with ice-cold PBS. Pelleted cells were resuspended in 0.5 ml of ice-cold phosphatebuffered saline to which 0.5 ml of ice-cold 4% phosphate-buffered paraformaldehyde (pH 7.2) containing 160 g/ml L-␣-lysophophatidylcholine (Lysolecithin, Sigma) was added dropwise under constant swirling. The cell suspension was kept on ice for 5 min after which the reaction was stopped by the addition of 2 ml phosphate-buffered saline/ bovine serum albumin. Cells were pelleted and resuspended in 300 l of phosphate-buffered saline/1% bovine serum albumin containing 8 g/ml 7AAD (Molecular Probes, Eugene, OR) and incubated in darkness for at least 30 min at room temperature prior to analysis on a FACSort flow cytometer (BD Biosciences). Typically, at least 10,000 events per sample were acquired, and data were analyzed using CELLQuest software (BD Biosciences, Immunocytometry Systems, San José, CA). Senescence-associated ␤-galactosidase staining was performed as described (43) .
Lentivirus Production and Transduction-Details of the lentiviral transfer vectors used in this study will be published elsewhere. Briefly, pRRLcpptpgkmcspreSin (44) was adapted by insertion of an internal ribosome entry site (IRES) of encephalomyocarditis virus within its polylinker. The enhanced form GFP (eGFP) coding sequence was cloned directly downstream of the IRES to yield pLVbcG. cDNA sequences corresponding to wild-type CDK4 and CDK4(R24C) (45) were cloned upstream of the IRES to generate pCDK4bcG and pCDK4(R24C)bcG, respectively. Replication-incompetent self-inactivating (SIN) lentiviruses, pseudotyped with vesicular stomatitis virus G protein (VSVg) were generated in 293T cells (44) . Briefly, the expression vectors for HIV Gag/Pol, HIV Rev, and VSVg and the viral transfer vector were co-transfected by the calcium phosphate method. Next day, the medium was changed and the supernatants were collected 48 h after transfection, filtered through a 0.45-m pore size filter and stored at Ϫ80°C.
The virus titer was estimated by determining HIV p24
gag protein by HIV-1 p24 antigen ELISA (ZeptoMetrix Corporation, NY). For transductions 5 ϫ 10 4 Lac-hSNF5 cells were seeded in 10-cm-diameter dishes and incubated overnight with 50 ng of virus in the presence of 8 g/ml polybrene. Next day, the medium was changed, and 2 days after transduction, the cells were harvested, seeded, and induced with IPTG for growth curves, colony-forming assays or FACS analysis. FACS sorting for eGFP expression revealed a 70 -90% transduction efficiency.
siRNA Knockdown of p16
INK4a
-The siRNA duplex oligonucleotides (sense: 5Ј-CGCACCGAAUAGUUACGGUTT-3Ј; antisense: 5Ј-ACCGU-AACUAUUCGGUGCGTT-3Ј) corresponding to positions 93-111-bp downstream of the p16
INK4a ATG initiation codon to which 2 additional Ts were added. 20 M RNA oligonucleotide stocks were prepared in 10 mM Tris, pH 7.5, 20 mM NaCl. The solution was incubated for 2 min at 95°C and then allowed to slowly cool to room temperature. For transfection, 3 ϫ 10 4 Lac-hSNF5 cells per well were seeded in 6-well plates containing 1 ml of media. 1-h prior transfection, Lac-hSNF5 cells were induced by addition of IPTG. For each well, 10 l of oligonucleotide stock (20 M) was diluted into 175 l of Opti-MEM serum-free medium (Invitrogen). Next, 4 l of Oligofectamine reagent (Invitrogen) was diluted in serum-free Opti-MEM media by gentle mixing and following a 10 min incubation added to the oligonucleotide solution, mixed gently, and incubated at room temperature for 15-20 min. Next, 200 l of the solution was added to each well. Cells were incubated 4 h at 37°C prior to the addition of 2 ml of fresh media either lacking or containing IPTG. The transfection was repeated every 72-96 h for a maximum of three consecutive transfections. At the indicated time points, cells were collected for different assays performed as described above.
Protein and mRNA Expression Analysis-Cell extracts were prepared in radioimmune precipitation assay buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 1% NaDOC, 0.1% SDS), assayed for protein concentration, and 15 g (45 g for p14 ARF blot) of extract was resolved by SDS-PAGE, and analyzed by immunoblotting. Primary antibodies: 5D4, Upstate Biotechnology for cyclin D1, C-19 (p21 cip1 ), M20 (cyclin E), H432 (cyclin A), C22 (cdk4), DO-1 (p53), SMP14 (HDM2), H88 (BRG1), H-116 (BAF170), H-76 (BAF155) all from Santa Cruz Biotechnology, G3-245 (BD Pharmingen) for pRb, FLAG-M2 (Sigma), Hermes-1, and H4C4 (DSHB, University of Iowa) for CD44; antitropomyosin (TM311, T Promoter Assays and Chromatin Immunoprecipitations-Cells were plated and transfected with the appropriate reporter plasmid and pCDNA-lacZ control plasmid using FuGENE 6 (Roche Applied Science). 12 h later, IPTG was added and after 24 or 48 h, cells were harvested and assayed for luciferase and ␤-galactosidase activity as described (48) . The following reporter plasmids were used: p16(-869)-luc (49), p14(-800)-luc (50) and p21-luc. ChIP assays were performed essentially as published (51) . Cross-linked chromatin was prepared from cells harvested 48 h after IPTG addition and sheared to an average length of 0.6 kb. After immunoprecipitation with antibodies against Ac-H3 (Upstate Biotechnology 06 -599), BRG1, hSNF5 or FLAG-M2 (Sigma). The recovered DNA was analyzed by PCR with primers corresponding to the p16 INK4a promoter, AGGAGCCCAGTCCTCCTT and CGGTATCTTTC-CAGGCAA; p14 ARF promoter, GCTGCCTGGAGTTGCGTT and AA-GATCTCGGAACGGCTC; or CD44 promoter, CCGTGCTCTGCTGAG-GCTGTA and GAAACCCAGAGATCTTGCTCC. Products were resolved on a 2.0% agarose gel and visualized by ethidium bromide staining.
RESULTS

Expression of hSNF5 in MRT Cells Blocks Cell Proliferation
and Induces Senescence-The aim of our study was to elucidate the pathway controlled by hSNF5 whose disruption causes tumorigenic transformation of MRT cells. Therefore, we reintroduced the hSNF5 gene under control of the Lac repressoroperator system. We established "Lac-hSNF5" cells derived from G401 MRT parental cells. These cells lack the hSNF5 gene but express wild-type p53 and pRb. In Lac-hSNF5 cells, the expression of hSNF5, tagged with a C-terminal FLAG epitope, is under the control of the lac operator and can be induced by addition of IPTG. Immunofluorescence experiments demonstrated that, while there is no detectable hSNF5 in the absence of IPTG, in its presence, hSNF5 is induced and localizes to the nucleus (Fig. 1A) . The level of hSNF5 in Lac-hSNF5 cells upon induction with IPTG is comparable or even less than that observed in other cell lines, as established by Western immunoblotting (Fig. 1B) . Because hSNF5 functions as a component of the SWI/SNF complex, we tested its association with BAF155, BAF170, and BRG1 (Fig. 1C) . BRG1 is the only human SWI2/SNF2p homologue expressed in G401 cells (data not shown). In extracts prepared from IPTG-induced cells, hSNF5 was found associated with immunoprecipitated BRG1 and, conversely, BRG1, BAF155, and BAF170 were present in hSNF5-FLAG immunoprecipitates (Fig. 1C) . The anti-FLAG beads did not immunoprecipitate BRG1, BAF155 or BAF170 in the absence of IPTG or in extracts prepared from the Lac-empty control cell line. In summary, we have generated an MRT-derived cell line in which hSNF5 expression can be tightly controlled. The induced hSNF5 appropriately localizes in the nucleus and associates with a BRG1-containing SWI/SNF complex.
Our establishment of the Lac-hSNF5 cells allowed us to assess the role of hSNF5 in the control of cell proliferation. First, we determined the growth curves of these cells in the presence of serum. Notably, like the parental G401 cells, un-
FIG. 1. Inducible expression of hSNF5 in MRT cells.
A, expression of hSNF5-FLAG in Lac-hSNF5 cells was determined in either the presence or absence of IPTG by immunofluorescence using the anti-FLAG antibody. DNA was visualized by DAPI staining. B, hSNF5 expression in distinct cell lines. Western immunoblotting analysis of hSNF5 expression in either non-induced or induced Lac-hSNF5 cells, Hela, T98G, or 911 cells. Cell lysates were resolved by SDS-PAGE and analyzed by Western immunoblotting using antibodies against hSNF5. Tropomyosin (TM) serves as a loading control. C, hSNF5-FLAG associates with BRG1. Extracts prepared from either Lac-Empty control cells or Lac-hSNF5 cells, grown in either the absence or presence of IPTG were incubated with beads coated with antibodies directed against either BRG1 or the FLAG epitope. Proteins retained on the beads were resolved by SDS-PAGE and analyzed by Western immunoblotting using antibodies against either the FLAG epitope, BRG1, BAF155, or BAF170.
hSNF5 Induces Cellular Senescence through p16
INK4a induced Lac-hSNF5 cells can proliferate in the absence of serum (data not shown). We found that hSNF5 induction dramatically impaired cell proliferation, even when cultured in the presence of 10% serum ( Fig. 2A) . In contrast, addition of IPTG had no effect on Lac-empty control cells lacking the hSNF5 gene. Similar results were obtained with independently isolated Lac-hSNF5 cell lines (data not shown). We also assessed the effect of hSNF5 on the colony-forming capacity of LachSNF5 cells, and found that hSNF5 expression dramatically reduced the number of colonies formed, after seeding these cells at a very low density (Fig. 2B) .
We next determined which stage of the cell cycle is affected by hSNF5. As shown in Fig. 2C , expression of hSNF5 leads to impaired DNA synthesis, indicated by the strongly reduced incorporation of BrdUrd. FACS analysis revealed that the hSNF5-expressing cells accumulate in G 1 , suggesting that the -induced) . F, senescence-associated ␤-galactosidase activity in Lac-hSNF5 and Lac-Empty cells grown either in the presence or absence of IPTG. G, apoptotic cells were identified by indirect immunofluorescence using antibodies against cytochrome c to monitor its release from the mitochondria and antibodies specific for cleaved PARP. DNA was visualized by DAPI staining. Cell counting revealed that the proportion of apoptotic cells increased from less than 1% to over 5%, following hSNF5 expression.
INK4a cell cycle block affects entry into S-phase (Fig. 2D) . The difference in percentage of gated cells at a given stage of the cell cycle in cells expressing hSNF5 versus uninduced cells is shown in Fig. 2E . Finally, we found that a large proportion of the hSNF5-expressing cells displayed the characteristic features of cellular senescence, including an enlarged, flat cell morphology and the presence of activated acidic ␤-galactosidase (Fig. 2F) . We also examined the effect of hSNF5 induction on apoptosis. There was a clear increase in the number of apoptotic cells, from less than 1% to more than 5%, following hSNF5 expression, as determined by the release of cytochrome c from mitochondria, the presence of the caspase 3 substrate cleaved PARP and a DAPI staining characteristic for apoptotic cells (Fig. 2G) . Because, at least in these cells, the induction of cell cycle arrest appears to be the major cause of the proliferative block, we decided to focus on the role of hSNF5 in cell cycle control rather than apoptosis. In conclusion, our results, and those of others (38 -41) , demonstrated that hSNF5 re-expression in MRT cells blocks cell proliferation and activates the cellular senescence program. However, the mechanism through which hSNF exerts its antiproliferative function remained unknown.
hSNF5 Activates p16 INK4a , but Not p14 ARF Expression-To delineate the pathway by which hSNF5 expression can reverse a tumor cell phenotype, we sought to identify effectors of cell cycle arrest and senescence that are activated by hSNF5. Since the INK4a/ARF locus is believed to play a prominent role in these processes, we first analyzed the expression of p14 ARF and p16
INK4a in Lac-hSNF5 cells (Fig. 3A) . Western immunoblotting revealed a strong up-regulation of p16
INK4a protein levels following hSNF5 expression, whereas no increase or even a small reduction of p14 ARF was observed. In common with other cells containing wild-type p53, p14
ARF levels are very low in Lac-hSNF5 cells. For comparison, we have loaded 3-fold less HeLa cell extract in which p14
ARF was readily detected. The extracts shown in Fig. 3A were harvested 4 days after induction of hSNF5. It should be noted that the onset of p16
INK4a induction varied between different experiments and has been detected as early as day 1 or as late as day 5.
Because p16 INK4a is a specific inhibitor of the Rb-regulating cyclin D1-CDK4 complex, we determined the phosphorylation status of pRb in Lac-hSNF5 cells. In support of a role of hSNF5 in activating the expression of p16
INK4a , pRb became hypophosphorylated following hSNF5 induction. As might be expected for cells arrested in G 1 , the levels of cyclins A, D, and E were reduced in hSNF5-expressing cells whereas we observed no major changes in CDK4. The levels of HDM2, p53, BAX, and p21 CIP1 remained largely unchanged, indicating that, at least in these cells, hSNF5 has no major effects upon the p53 pathway. Finally, it is of interest to note that the CD44 gene, encoding a family of cell surface glycoproteins whose overexpression is often associated with tumor metastasis (52) , is down-regulated after hSNF5 induction.
We next tested whether the increase of 16 INK4a protein resulted from enhanced mRNA levels, using RT-PCR. As shown in Fig. 3B, p16 INK4a mRNA expression is clearly induced in hSNF5-expressing cells. In contrast, we consistently observed a robust reduction in CD44, cyclin A, D1, and E mRNA levels, a modest reduction of p14 ARF mRNA, while expression of p21
CIP1
and GAPDH was not influenced by hSNF5. INK4a , but not p14 ARF , by hSNF5 suggests that it acts in a promoter-selective manner. To explore this idea further, we used transient transfection assays to compare the effects of hSNF5 expression on a number of distinct promoters (Fig. 4A) . While hSNF5 induction activated the p16
INK4a promoter, the p14 ARF and p21 CIP1 promoters were not significantly affected. These results are in good agreement with the effects of hSNF5 expression on the corresponding endogenous genes, and establish that hSNF5 acts as a promoter-specific transcription factor.
Since hSNF5 is in a complex with BRG1 and activates the p16
INK4a promoter, we tested whether hSNF5 plays a role in promoter targeting of the hSWI/SNF complex. We utilized formaldehyde cross-linking and chromatin immunoprecipitation (ChIP) to study the occupancy of the p16
INK4a and p14 ARF promoters in living cells. Using either control beads or beads coupled with antibodies against hyperacetylated histone H3, FLAG, or BRG1, we immunoprecipitated chromatin isolated from Lac-hSNF5 cells (Fig. 4B) . Hyperacetylated histone H3 was present at the p16 INK4a promoter, irrespective of whether it is active (hSNF5 expressed), or not (hSNF5 silent). In contrast, hyperacetylated histone H3 was not associated with the p14 ARF promoter. After induction, hSNF5-FLAG bound to the FIG. 3 . Effects of hSNF5 expression on regulators of cell cycle progression and apoptosis. A, analysis of cell lysates prepared from Lac-hSNF5 cells harvested 4 days after plating. Equal amounts of protein were separated by SDS-PAGE, followed by Western immunoblotting, using antibodies directed against the indicated proteins. As a reference for p14 ARF levels, 3-fold less of HeLa cell extract was loaded. Hypo-(pRb) and hyperphosphorylated (ppRb) retinoblastoma protein are indicated; cycl., cyclin; Tub., tubulin. B, RT-PCR analysis of gene expression in Lac-hSNF5 cells. mRNA was isolated 48 h after induction of hSNF5 with IPTG. To detect transcripts from the INK4a/ARF locus, primer sets were used that correspond to the shared exon 2 and either exon 1␤ or 1␣, which are unique for p14 ARF and p16 INK4a mRNA, respectively. The same mRNA isolates were used to detect p21
Cip1
, cyclins A, E, and D1, CD44, and GAPDH expression, using primer sets corresponding to each mRNA.
hSNF5 Induces Cellular Senescence through p16
INK4a p16
INK4a promoter. Strikingly, only in hSNF5-expressing cells is BRG1 found associated with the p16
INK4a promoter. It should be noted that hSNF5 expression does not affect BRG1 levels (see Fig. 1C ). Neither hSNF5 nor BRG1 was detected at the p14 ARF promoter. These results suggest that the SWI/SNF complex is recruited to the p16
INK4a promoter to stimulate transcription, and that its tethering is hSNF5-dependent.
Next, we performed ChIP experiments on the CD44 promoter to determine the role of hSNF at a promoter that is repressed upon its induction. In cells lacking hSNF5, when CD44 is highly expressed, BRG1 was not detectable at the promoter (Fig. 4C, top panel) . In agreement with its high activity, histone H3 at the CD44 promoter appears to be hyperacetylated. Following its induction, hSNF5 but also BRG1 are bound to the CD44 promoter (Fig. 4C, bottom panel) . Interestingly, histone H3 at the promoter became hypo-acetylated. Thus, concomitant with hSNF5-dependent repression of the CD44 promoter, the SWI/SNF complex was recruited and histones were de-acetylated. Taken together, our results suggest that hSNF5 is a dualistic transcriptional co-regulator, which can mediate gene activation as well as repression. The molecular mechanism of hSNF5 function at both the activated p16
INK4a
promoter and the repressed CD44 promoter involves BRG1 recruitment.
hSNF5 Induces Cell Cycle Arrest and Cellular Senescence through p16 INK4a -Having established that the p16 INK4a gene is a major target for activation by hSNF5, we investigated the consequences of its activation in MRT cells. We first tested whether activation of p16
INK4a alone would be sufficient to drive cell cycle arrest and induction of senescence. To this end, we overexpressed p16
INK4a in the absence of hSNF5 induction.
Lac-empty cells transfected with a vector expressing p16
INK4a displayed a clear senescence phenotype, which was not observed after transfection with an empty vector (Fig. 5) . Thus, our results demonstrate that hSNF5 up-regulates p16
INK4a , and that stimulation of p16
INK4a expression suffices to activate the cellular senescence program in MRT-derived cells. However, they do not exclude alternative hSNF5-dependent growth control pathways or unambiguously establish the critical requirement of p16
INK4a for cellular senescence in these cells. p16
INK4a exerts its effect by inhibiting the activity of CDK4, thereby maintaining pRb in its active, antiproliferative state. We therefore asked whether expression of a tumor-associated mutant form of CDK4, CDK4 R24C (45) , which is insensitive to kinase inhibition by p16
INK4a , could override the hSNF5-induced arrest. We utilized recombinant lentiviruses to express either CDK4 or CDK4 R24C in Lac-hSNF5 cells. As shown in Fig.  6A , expression of the p16
INK4a -insensitive mutant CDK4 R24C , but not of wild type CDK4, counteracts the hSNF5-mediated block of cell proliferation. Using Western immunoblotting, we confirmed that the p16
INK4a induction by hSNF5 was not affected in these cells (Fig. 6B) . The obstruction of hSNF5-induced cell cycle arrest by CDK4
R24C was also observed in colony-formation assays (Fig. 6C) Cip1 genes. Following transfection, cells were grown in either the presence of absence of IPTG and harvested after 24 (day 1) or 48 h (day 2). The luciferase activities were normalized for the corresponding reporter values without IPTG. B, hSNF5 is required for BRG1 binding to the p16
INK4a promoter. ChIPs from Lac-hSNF5 cells using antibodies against hyperacetylated histone H3 (anti-Ac-H3), hSNF5-FLAG (anti-FLAG), or BRG1. The ChIPs were analyzed by PCR using the indicated primer sets flanking either the p16
INK4a or the p14 ARF promoter. INK4a (black rectangles) are indicated. C, ChIP assays, performed as described above were used to determine the role of hSNF5 in BRG1 recruitment to the repressed CD44 promoter.
FIG. 5. Overexpression of p16
INK4a can induce cellular senescence. Lac-empty cells were transiently transfected with either an empty control vector (CMV-empty) or with a vector expressing p16
INK4a
driven by the CMV promoter (CMV-p16). Senescence-associated ␤-galactosidase activity was determined 5 days after transfection.
hSNF5 Induces Cellular Senescence through p16 INK4a 
FIG. 6. p16
INK4a
-insensitive CDK4
R24C overrules the hSNF5-induced block to cell proliferation. Recombinant lentiviruses were used to transduce Lac-hSNF5 cells to express GFP and either no additional protein (LV-empty), wild-type CDK4 (LV-CDK4), or CDK4 R24C (LV-CDK4
R24C
), in addition to. A, proliferation curves for lentivirus infected Lac-hSNF5 cells grown in either the presence (closed circles) or absence of IPTG (open circles). All S.D. were less than 10%. B, extracts were prepared from these cells and equal amounts of protein were separated by SDS-PAGE followed by Western immunoblotting using antibodies directed against the indicated proteins. Tropomyosin (TM) serves as a loading control. C, effect of CDK4 R24C expression on the hSNF5-dependent proliferative block was tested by colony-formation assays. D, FACS analysis of the effect of CDK4
R24C expression on the cell cycle distribution of Lac-hSNF5 cells grown in either the presence or absence of IPTG, as determined by FACS analysis. Results were represented as described in Fig. 1E , showing the difference in percentage of gated cells at a given stage of the cell cycle of induced versus uninduced cells.
hSNF5 Induces Cellular Senescence through p16
INK4a the accumulation of cells in the G 1 phase of the cell cycle upon
